ProfileGDS5678 / 1440734_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 39% 39% 39% 40% 37% 42% 37% 48% 37% 38% 39% 37% 45% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9348139
GSM967853U87-EV human glioblastoma xenograft - Control 22.9001739
GSM967854U87-EV human glioblastoma xenograft - Control 32.8881339
GSM967855U87-EV human glioblastoma xenograft - Control 42.8609240
GSM967856U87-EV human glioblastoma xenograft - Control 52.8002137
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0677842
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9039937
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1349648
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.825837
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8452338
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8830739
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8214137
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0610145
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8908439